- Home
- PMEC vs NERV Comparison
PMEC vs NERV Comparison
Compare PMEC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- NERV
- Stock Information
- Founded
- PMEC 1984
- NERV 2007
- Country
- PMEC Singapore
- NERV United States
- Employees
- PMEC N/A
- NERV N/A
- Industry
- PMEC
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- NERV Health Care
- Exchange
- PMEC Nasdaq
- NERV Nasdaq
- Market Cap
- PMEC 23.4M
- NERV 20.1M
- IPO Year
- PMEC 2023
- NERV 2014
- Fundamental
- Price
- PMEC $0.61
- NERV $2.83
- Analyst Decision
- PMEC
- NERV Hold
- Analyst Count
- PMEC 0
- NERV 1
- Target Price
- PMEC N/A
- NERV $5.00
- AVG Volume (30 Days)
- PMEC 64.4K
- NERV 16.2K
- Earning Date
- PMEC 09-26-2024
- NERV 11-05-2024
- Dividend Yield
- PMEC N/A
- NERV N/A
- EPS Growth
- PMEC N/A
- NERV N/A
- EPS
- PMEC N/A
- NERV N/A
- Revenue
- PMEC $72,524,000.00
- NERV N/A
- Revenue This Year
- PMEC N/A
- NERV N/A
- Revenue Next Year
- PMEC N/A
- NERV N/A
- P/E Ratio
- PMEC N/A
- NERV N/A
- Revenue Growth
- PMEC 5.07
- NERV N/A
- 52 Week Low
- PMEC $0.49
- NERV $2.26
- 52 Week High
- PMEC $4.18
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- PMEC 53.28
- NERV 51.29
- Support Level
- PMEC $0.58
- NERV $2.50
- Resistance Level
- PMEC $0.66
- NERV $2.77
- Average True Range (ATR)
- PMEC 0.05
- NERV 0.11
- MACD
- PMEC 0.00
- NERV 0.02
- Stochastic Oscillator
- PMEC 55.22
- NERV 79.17
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.